Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study): a randomised, placebo-controlled, double-blind trial

Wancata, 2003, Number of dementia sufferers in Europe between the years 2000 and 2050, Eur Psychiatry, 18, 306, 10.1016/j.eurpsy.2003.03.003 Desai, 2004, Activities of daily living in patients with dementia: clinical relevance, methods of assessment and effects of treatment, CNS Drugs, 18, 853, 10.2165/00023210-200418130-00003 Yaffe, 2002, Patient and caregiver characteristics and nursing home placement in patients with dementia, JAMA, 287, 2090, 10.1001/jama.287.16.2090 Jönsson, 2006, Determinants of costs of care for patients with Alzheimer's disease, Int J Geriatr Psychiatry, 21, 449, 10.1002/gps.1489 Maelicke, 2000, Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease, Eur J Pharmacol, 393, 165, 10.1016/S0014-2999(00)00093-5 Aguero-Torres, 1998, Natural history of Alzheimer's disease and other dementias: review of the literature in the light of the findings from the Kungsholmen Project, Int J Geriatr Psychiatry, 13, 755, 10.1002/(SICI)1099-1166(1998110)13:11<755::AID-GPS862>3.0.CO;2-Y Loy, 2006, Galantamine for Alzheimer's disease and mild cognitive impairment, Cochrane Database Syst Rev, 10.1002/14651858.CD001747.pub3 Loveman, 2006, The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease, Health Technol Assess, 10, 3, 10.3310/hta10010 Folstein, 1975, “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician, J Psychiatr Res, 12, 189, 10.1016/0022-3956(75)90026-6 Wilkinson, 2002, Galantamine provides broad benefits in patients with 'advanced moderate' Alzheimer's disease (MMSE < or = 12) for up to 6 months, Int J Clin Pract, 56, 509, 10.1111/j.1742-1241.2002.tb11310.x Blesa, 2003, Galantamine provides sustained benefits in patients with 'advanced moderate' Alzheimer's disease for at least 12 months, Dement Geriatr Cogn Disord, 15, 79, 10.1159/000067974 Feldman, 2001, A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease, Neurology, 57, 613, 10.1212/WNL.57.4.613 Winblad, 2006, Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study, Lancet, 367, 1057, 10.1016/S0140-6736(06)68350-5 Black, 2007, Donepezil preserves cognition and global function in patients with severe Alzheimer disease, Neurology, 69, 459, 10.1212/01.wnl.0000266627.96040.5a 2000 McKhann, 1984, Clinical diagnosis of Alzheimer's disease: report of the NINCDS–ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease, Neurology, 34, 939, 10.1212/WNL.34.7.939 Roman, 1993, Vascular dementia: diagnostic criteria for research studies. Report of the NINDS–AIREN International Workshop, Neurology, 43, 250, 10.1212/WNL.43.2.250 Albert, 1992, The test for severe impairment: an instrument for the assessment of patients with severe cognitive dysfunction, J Am Geriatr Soc, 40, 449, 10.1111/j.1532-5415.1992.tb02009.x Hawes, 1997, Development of the nursing home Resident Assessment Instrument in the USA, Age Ageing, 26, 19, 10.1093/ageing/26.suppl_2.19 Morris, 1999, Scaling ADLs within the MDS, J Gerontol A Biol Sci Med Sci, 54, M546, 10.1093/gerona/54.11.M546 Panisset, 1994, Severe impairment battery. A neuropsychological test for severely demented patients, Arch Neurol, 51, 41, 10.1001/archneur.1994.00540130067012 Raskind, 2000, Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group, Neurology, 54, 2261, 10.1212/WNL.54.12.2261 Tariot, 2000, A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group, Neurology, 54, 2269, 10.1212/WNL.54.12.2269 Reisberg, 2003, Memantine in moderate-to-severe Alzheimer's disease, N Engl J Med, 348, 1333, 10.1056/NEJMoa013128 2007 Feldman, 2005, Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial, Int J Geriatr Psychiatry, 20, 559, 10.1002/gps.1325 SBU. Dementia and mortality. In: Dementia: a systematic review, vol 2. Stockholm: The Swedish Council on Technology Assessment in Health Care (SBU), 2008: 527–49. Feldman, 2008, Analyses of mortality risk in patients with dementia treated with galantamine, Acta Neurol Scand Winblad, 2008, Safety and efficacy of galantamine in subjects with mild cognitive impairment, Neurology, 70, 2024, 10.1212/01.wnl.0000303815.69777.26 Marrie, 2000, Community-acquired pneumonia in the elderly, Clin Infect Dis, 31, 1066, 10.1086/318124 Riquelme, 1996, Community-acquired pneumonia in the elderly: a multivariate analysis of risk and prognostic factors, Am J Respir Crit Care Med, 154, 1450, 10.1164/ajrccm.154.5.8912763 Feldman, 2006, Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment, Alzheimer Dis Assoc Disord, 20, 263, 10.1097/01.wad.0000213859.35355.59